News
Home>
News
News
-
Company NewsFirst Patient Enrolled in Phase III Registrational Clinical Trial of Tecotabart vedotin for First-Line Treatment of Gastric Cancer
On April 15, LaNova Medicines, a wholly-owned subsidiary of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), announced the successful enrollment of the first patient in the Phase III registrational clinical trial of its independently developed Class 1 new drug, Tecotabart vedotin (LM-302, a CLDN18.2 ADC), combined with a PD-1 inhibitor for the first-line treatment of CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.2026-04-16 -
Company NewsJointly Promoting New Development in China-UAE Economic and Trade Cooperation! China-UAE Business and Investment Promotion Conference Held in Beijing, Eric Tse Invited to Attend the Opening Ceremony
On April 13, the "China-UAE Business and Investment Promotion Conference", jointly hosted by the Ministry of Commerce of the People's Republic of China and the Ministry of Foreign Trade of the United Arab Emirates, was held in Beijing.2026-04-15 -
Company NewsSBP Group Enters the Era of Domesticated "10,000-Liter Scale" Biologic Production Lines
From "emerging and cultivating" to a "strategic pillar", as China's biopharmaceutical industry enters a new stage of high-quality development, mere capacity expansion is no longer the sole measure of a company's core competitiveness.2026-04-13 -
%20%E6%8B%B7%E8%B4%9D.jpg)
Company NewsOnce-Yearly Dosing, Targeting Cardiovascular Disorders, First US Patient Enrolled in China-US Phase II Clinical Trial of Hygieia's Kylo-11
On April 8 (local time), Kylo-11 (LPA-siRNA), independently developed by Hygieia, a wholly-owned subsidiary of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), achieved the enrollment of the first US patient in the United States for its Phase II clinical trial in patients with atherosclerotic cardiovascular diease (ASCVD) and elevated lipoprotein (a) [Lp(a)].2026-04-10 -
Company News
Policy Empowers Innovation Implementation! Naldemedine Launched in the Guangdong-Hong Kong-Macao Greater Bay Area, Accelerating Benefits for Domestic OIC Patients
Opioid-induced constipation (OIC) is one of the most common symptoms in cancer patients, affecting approximately 60%-90% of cancer patients using opioids for pain relief.2026-04-09 -
Company NewsSBP Group's Pan-KRAS Inhibitor TQB3205 Secures Clinical Trial Approvals in both China and the US
Following its clinical trial approval in China this March, TQB3205, a Class 1 innovative oral Pan-KRAS inhibitor independently developed by Chia Tai Tianqing, a core subsidiary of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), received approval from the U.S. Food and Drug Administration (FDA) on April 4 (local time), to conduct clinical trials for advanced malignant tumors.2026-04-08 -
Company NewsAuthoritative Citeline Report: SBP Group Ranks 14th Globally in Pipeline Scale, Demonstrating "Impressive Achievement"
Recently, the internationally renowned consulting firm Citeline released the "Pharma R&D Annual Review 2026" and introduced a new, more precise analytical method to select the "Top 25 Global Pharmaceutical Companies by Pipeline Scale".2026-04-03 -
Company NewsNew Progress in Breakthrough Therapy for Rare Disease! Chia Tai Tianqing Successfully Enrolls First Patient in Phase III Clinical Trial of TQ-B3234
Recently, Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), announced that the first patient has been enrolled in a Phase III clinical trial of the Class 1 new drug TQ-B3234 capsules (a MEK1/2 inhibitor) at Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine (abbreviated as Shanghai Ninth People’s Hospital).2026-04-02 -
Company NewsPutting the "Patriotism and Love for Hong Kong" Initiative into Practice, the "Mong Kok Community Living Room" Funded by Cheng Cheung Ling Officially Opens
On the morning of March 30, the "Mong Kok Community Living Room," sponsored by a donation from Ms. Cheng Cheung Ling, President of the Hong Kong Chinese Friendship Association, President of Chia Tai Pharmaceutical Group, and Vice Chair of the Board of Directors of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), officially opened. This marks another important addition to the HKSAR Government's "Community Living Room Pilot Scheme," bringing warm care and tangible support to grassroots families in the Yau Tsim Mong District.2026-03-31 -
Company NewsWorld's Fastest-Progressing HER2 Bispecific ADC! Another Phase III Breast Cancer Clinical Trial of TQB2102 Achieves Full Enrollment
Recently, a Phase III clinical trial (TQB2102-III-02) of TQB2102, a HER2 bispecific dual-epitope antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), for HER2-positive advanced breast cancer, has completed full enrollment of all subjects.2026-03-30